- Home
- XOMAP vs ISPC Comparison
XOMAP vs ISPC Comparison
Compare XOMAP & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- ISPC
- Stock Information
- Founded
- XOMAP N/A
- ISPC 2009
- Country
- XOMAP United States
- ISPC United States
- Employees
- XOMAP 13
- ISPC N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- XOMAP Health Care
- ISPC Health Care
- Exchange
- XOMAP Nasdaq
- ISPC Nasdaq
- Market Cap
- XOMAP N/A
- ISPC N/A
- IPO Year
- XOMAP N/A
- ISPC 2021
- Fundamental
- Price
- XOMAP $25.93
- ISPC $1.26
- Analyst Decision
- XOMAP
- ISPC
- Analyst Count
- XOMAP 0
- ISPC 0
- Target Price
- XOMAP N/A
- ISPC N/A
- AVG Volume (30 Days)
- XOMAP N/A
- ISPC 47.1K
- Earning Date
- XOMAP N/A
- ISPC 05-06-2025
- Dividend Yield
- XOMAP N/A
- ISPC N/A
- EPS Growth
- XOMAP N/A
- ISPC N/A
- EPS
- XOMAP N/A
- ISPC N/A
- Revenue
- XOMAP N/A
- ISPC $10,390,702.00
- Revenue This Year
- XOMAP N/A
- ISPC $13.82
- Revenue Next Year
- XOMAP N/A
- ISPC $11.76
- P/E Ratio
- XOMAP N/A
- ISPC N/A
- Revenue Growth
- XOMAP N/A
- ISPC 0.74
- 52 Week Low
- XOMAP N/A
- ISPC $1.03
- 52 Week High
- XOMAP N/A
- ISPC $11.80
- Technical
- Relative Strength Index (RSI)
- XOMAP 58.85
- ISPC 27.68
- Support Level
- XOMAP $25.73
- ISPC $1.03
- Resistance Level
- XOMAP $25.93
- ISPC $1.44
- Average True Range (ATR)
- XOMAP 0.09
- ISPC 0.09
- MACD
- XOMAP 0.03
- ISPC -0.00
- Stochastic Oscillator
- XOMAP 93.11
- ISPC 7.14
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.